Surgical Science Sweden AB (publ) (SUSRF) Stock Analysis

Surgical Science Sweden AB (publ) (SUSRF) Healthcare & Pipeline Overview

Surgical Science Sweden AB (publ) develops and markets virtual reality surgical simulators, offering evidence-based training solutions for laparoscopic, endoscopic, and robotic procedures. With a focus on enhancing surgical skills and patient safety, the company addresses the growing demand for advanced medical training technologies within the healthcare sector.

What Is the Investment Thesis for SUSRF?

Surgical Science Sweden AB (publ) presents a notable research candidate within the growing market for surgical simulation. The company's focus on virtual reality training solutions for laparoscopic, endoscopic, and robotic surgery aligns with the increasing demand for advanced medical education and patient safety. With a P/E ratio of 28.17 and a profit margin of 6.7%, the company demonstrates financial stability and growth potential. Key value drivers include the expansion of its product portfolio, penetration into new geographic markets, and the increasing adoption of simulation-based training in healthcare. Ongoing catalysts include partnerships with medical institutions and the development of new simulation modules for emerging surgical techniques. Potential risks include competition from other simulation providers and the adoption rate of VR technology in surgical training.

Based on FMP financials and quantitative analysis

SUSRF Key Highlights

Market Cap of $265M indicates a relatively small but established player in the medical simulation market.

• P/E Ratio of 28.17 suggests the company is valued reasonably compared to its earnings.
• Profit Margin of 6.7% demonstrates profitability, although there is room for improvement compared to industry leaders.
• Gross Margin of 63.9% highlights the company's ability to efficiently manage production costs.
• Beta of 0.59 indicates lower volatility compared to the overall market, suggesting a more stable investment.

Who Are SUSRF's Competitors?

SUSRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SUSRF's Key Strengths?

Innovative virtual reality technology.

• Comprehensive product portfolio.
• Strong relationships with medical institutions.
• Established brand reputation.

What Are SUSRF's Weaknesses?

Relatively small market capitalization.

• Limited geographic presence.
• Dependence on technological advancements.
• Profit margin could be higher.

What Could Drive SUSRF Stock Higher?

Increasing adoption of virtual reality simulation in surgical training programs.

• Strategic partnerships with leading medical institutions to expand market reach.
• Development and launch of new simulation modules for emerging surgical techniques.
• Expansion into new geographic markets with high demand for surgical training.
• Integration of artificial intelligence to enhance the realism and effectiveness of surgical simulations.

What Are the Key Risks for SUSRF?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Rich valuation — a P/E of 28.17 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Competition from established medical device companies with larger resources.
• Technological obsolescence due to rapid advancements in virtual reality technology.
• Regulatory changes in the healthcare industry affecting the adoption of simulation-based training.
• Economic downturns leading to budget cuts in hospitals and training centers.
• Limited liquidity due to trading on the OTC market.

What Are the Growth Opportunities for SUSRF?

• Expansion into Emerging Markets: Surgical Science has the opportunity to expand its presence in emerging markets, where the demand for advanced medical training is growing rapidly. These markets often lack access to experienced surgeons and advanced medical facilities, making simulation-based training a valuable solution. By establishing partnerships with local hospitals and educational institutions, Surgical Science can tap into this underserved market and drive revenue growth. Timeline: 2-3 years. Market Size: Significant growth potential in Asia-Pacific and Latin America.
• Development of New Simulation Modules: Surgical Science can drive growth by continuously developing new simulation modules that address emerging surgical techniques and procedures. This includes expanding its offerings for robotic surgery, minimally invasive surgery, and other specialized areas. By staying at the forefront of surgical innovation, the company can attract new customers and retain existing ones. Timeline: Ongoing. Market Size: Continuous expansion based on new surgical advancements.
• Strategic Partnerships with Medical Institutions: Collaborating with leading medical institutions and universities can provide Surgical Science with access to valuable research, clinical expertise, and distribution channels. These partnerships can help the company refine its products, validate its training methodologies, and increase its market reach. Timeline: Ongoing. Market Size: Increased market penetration and brand recognition.
• Integration of Artificial Intelligence: Integrating AI into its simulation platforms can enhance the realism and effectiveness of surgical training. AI can be used to provide personalized feedback, adapt the difficulty level to the trainee's skill level, and simulate complex surgical scenarios. This can improve the learning experience and lead to better patient outcomes. Timeline: 3-5 years. Market Size: Enhanced training effectiveness and competitive advantage.
• Subscription-Based Revenue Model: Transitioning to a subscription-based revenue model can provide Surgical Science with a more predictable and recurring revenue stream. This model involves offering customers access to its simulation platforms and content on a subscription basis, rather than through one-time purchases. This can improve customer retention and increase the lifetime value of each customer. Timeline: 1-2 years. Market Size: Stable and recurring revenue stream.

What Are SUSRF's Competitive Advantages?

• Proprietary virtual reality technology.
• Strong relationships with leading medical institutions.
• Comprehensive suite of simulation products.
• Established brand reputation in the surgical simulation market.

What Does SUSRF Do?

Surgical Science Sweden AB (publ), founded in 1999 and headquartered in Gothenburg, Sweden, is a pioneering company in the field of virtual reality surgical simulation. The company develops and markets VR simulators designed to provide evidence-based training for laparoscopic and endoscopic surgical procedures. Its flagship product, the LapSim training system, includes LapSim ST, tailored for surgical technologists and assistants, and LapSim essence, a portable VR simulator. Surgical Science also offers the EndoSim system for endoscopy training, TeamSim for inter-professional teamwork development in surgery, Simball Box for velocity feedback, Simbionix simulators, and robotic surgery simulators. These products aim to enhance surgical skills, improve patient outcomes, and reduce the learning curve for surgeons and medical staff. Surgical Science's simulators are used in hospitals, training centers, and educational institutions worldwide, positioning the company as a key player in the advancement of surgical education and patient safety.

What Products and Services Does SUSRF Offer?

• Develops virtual reality simulators for surgical training.
• Offers simulators for laparoscopic procedures.
• Provides simulators for endoscopic procedures.
• Creates simulators for robotic surgery training.
• Offers training systems for surgical technologists and assistants.
• Develops platforms for inter-professional teamwork education in surgery.
• Provides tools for velocity feedback during surgical training.

How Does SUSRF Make Money?

• Sells virtual reality surgical simulators to hospitals and training centers.
• Generates revenue through the sale of simulation modules and software updates.
• Offers service and maintenance contracts for its simulators.
• Partners with medical institutions for research and development.

What Industry Does SUSRF Operate In?

Surgical Science Sweden AB (publ) operates within the healthcare information services industry, specifically focusing on medical simulation. The market for surgical simulation is growing due to the increasing emphasis on patient safety, the need for standardized training, and the adoption of new surgical techniques. The competitive landscape includes companies offering similar simulation solutions, such as AVCTF (Avantis Medical Systems), BOVNF (Bovie Medical), CLHLF (ClearSign Technologies), COGZF (Cogentix Medical), and HUMDF (Humacyte). Surgical Science differentiates itself through its focus on VR technology and its comprehensive suite of simulation products.

Who Are SUSRF's Key Customers?

• Hospitals and medical centers.
• Surgical training centers.
• Universities and medical schools.
• Medical device companies.

Surgical Science Sweden AB (publ) (SUSRF) Valuation Context

Valued at $265M, SUSRF is classified as a micro-cap stock.

SUSRF Revenue & Earnings Trend

In Q2 FY2026, SUSRF generated $26.0M in top-line revenue, marking a sequential increase of 7.2%. The company recorded net income of $2.1M, with diluted EPS of $0.04. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, SUSRF averaged $0.05 in diluted EPS.

Company Profile

Surgical Science Sweden AB (publ) operates in the Health Information Services industry within the Healthcare sector. It is headquartered in Gothenburg, Sweden.

Return on equity for Surgical Science Sweden AB (publ) stands at 2.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.9%, showing how much profit it generates from its asset base. SUSRF trades at a trailing price-to-earnings ratio of 28.17, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.5%, the inverse of the P/E and a quick read on earnings relative to price.

Surgical Science Sweden AB (publ)'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.44 places it in the safe zone, indicating low near-term bankruptcy risk.

Surgical Science Sweden AB (publ) has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 19.4% below estimates on average.

SUSRF Financials

SUSRF Latest News

SUSRF Analyst Consensus

SUSRF MoonshotScore

What Investors Ask About Surgical Science Sweden AB (publ) (SUSRF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources